Number (percentage) of patients with ≥ 1 positive enthesitis site at baseline (n = 143) and mean enthesitis scores among patients with baseline score ≥ 1 in individual enthesitis indices.
| Variables | Placebo, n = 73 | Adalimumab, n = 70 |
|---|---|---|
| LEI ≥ 1, n (%) | 51 (70) | 52 (74) |
| LEI, 0–6, mean (SD) | 2.3 (1.5) | 2.4 (1.5) |
| SPARCC Enthesitis Index ≥ 1, n (%) | 65 (89) | 64 (91) |
| SPARCC Enthesitis Index, 0–16, mean (SD) | 5.1 (3.6) | 5.0 (3.9) |
| MASES ≥ 1, n (%) | 65 (89) | 58 (83) |
| MASES, 0–13, mean (SD) | 4.5 (3.2) | 4.5 (3.5) |
LEI: Leeds Enthesitis Index; MASES: Maastricht Ankylosing Spondylitis Enthesitis Score; SPARCC: Spondyloarthritis Research Consortium of Canada.